We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Controversies |

Role of Cytogenetics in Management of Uveal Melanoma

Jerry A. Shields, MD; Carol L. Shields, MD; Miguel Materin, MD; Takami Sato, MD; Arupa Ganguly, PhD
Arch Ophthalmol. 2008;126(3):416-419. doi:10.1001/archopht.126.3.416.
Text Size: A A A
Published online


Uveal melanoma is one of the few conditions diagnosed by eye care specialists that carries a guarded prognosis for life. Although most patients are apparently healthy at the time of diagnosis, 10-year tumor-related death from posterior uveal melanoma ranges from 20% to greater than 50%.13

The management of posterior uveal melanoma has been controversial. Several years ago, heated debates erupted between 2 diametrically opposed schools of thought. One group favored prompt enucleation of virtually all melanocytic uveal lesions that were suspected to be melanomas.4,5 The other group preferred observation of many small- and medium-sized tumors to document growth before initiating treatment68; they proposed that enucleation might not improve the prognosis and could even accelerate dissemination of the neoplasm.6 The philosophy of “observation until growth is documented” has prevailed in ophthalmology during the last 30 years and some highly suspicious tumors that were probably melanomas were observed without treatment. The increased use of eye-saving modalities, such as irradiation, local resection, and transpupillary thermotherapy, has not resolved the controversy.9,10

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

17 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Genetic determinants of uveal melanoma. Tumour Biol 2014;35(12):11711-7.
Vitreous evaluation: a diagnostic challenge. Ophthalmology 2015;122(3):531-7.